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Original article
Isolated ileal blind loop inflammation after intestinal 
resection with ileocolonic anastomosis in Crohn’s 
disease: an often neglected endoscopic finding with 
an unfavorable outcome
Evelien M.J. Beelena, Annemarie C. de Vriesa, Alexander G. Bodelierb, Jolyn Moolenaara,  
W. Rudolph Schoutenc and C. Janneke van der Woudea  
Introduction
Intestinal surgery is a valuable treatment option in patients 
with Crohn’s disease (CD). Intestinal resection rates in CD 
patients are estimated at 50–70% within 10 years after 
diagnosis [1,2]. Patients with ileal or ileocolonic CD local-
ization have a higher likelihood of undergoing intestinal 
resection, with hazard ratios (HRs) of 3.4 and 3.3 respec-
tively, when compared with isolated colonic disease local-
ization [2,3]. Consequently, most frequently performed 
surgeries in CD patients are ileocecal resections or right 
hemicolectomies with ileocolonic anastomosis [2,4].
The benefits of surgery are substantial, and a recent 
randomized controlled trial demonstrated ileocolonic 
resection to be an alternative to step-up therapy with 
TNFα-blockers with regard to patient reported quality of 
life [5]. However, postoperative recurrence is highly prev-
alent, with endoscopic lesions recurring in up to 80% of 
patients within 1 year [6,7]. Current postoperative treat-
ment strategies aim at prevention, early detection and 
early medical treatment of endoscopic lesions [8,9]. In 
particular, publication of the Rutgeerts score as a tool to 
classify endoscopic lesions has influenced postoperative 
treatment and follow-up strategies. In the landmark study 
from Rutgeerts et al., the clinical recurrence rates 5 years 
after endoscopy were assessed in 89 postoperative CD 
patients, and estimated at 10% for Rutgeerts score of i0 
or i1, 25% for Rutgeerts score i2, 60% for Rutgeerts score 
i3 and 100% for Rutgeerts i4 [6].
Following the observation of mucosal lesions preceding 
clinical symptoms, the Rutgeerts score at ileocolonoscopy 
has gained a central role in guiding decisions on drug ther-
apy in postoperative CD patients. Pre-emptive ileocolo-
noscopy early after intestinal resection is recommended 
in international guidelines [9,10]. A randomised trial 
confirmed the importance of early ileocolonoscopy after 
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Objective Postoperative endoscopic recurrence in patients with Crohn’s disease (CD) is commonly classified using 
the Rutgeerts score. Ulcerations in the ileal blind loop are not taken into account in the Rutgeerts score, and the clinical 
relevance of these lesions is unknown. This study aimed to assess the outcome of isolated ileal blind loop inflammation (IBLI) 
in postoperative CD patients.
Methods Adult CD patients who underwent intestinal surgery with ileocolonic anastomosis between 1997 and 2017 were 
included and postoperative endoscopy reports were retrospectively reviewed. IBLI was defined as isolated inflammation of 
the ileal blind loop with or without ulcera confined to the anastomosis. Outcome was assessed using endoscopic recurrence 
(Rutgeerts >i2) and surgical recurrence (re-resection).
Results A total of 341 CD patients were included. In 125 out of 341 (37%) patients, the ileal blind loop was described in 
the endoscopy reports. IBLI was reported in 43 of 341 (13%) patients. Start or step-up drug therapy was initiated in 10 of 
32 (31%) IBLI patients with abdominal symptoms within a median of 0.9 months [interquartile range (IQR) 0.7–1.4] after 
ileocolonoscopy. Endoscopic recurrence occurred in 4 out of 38 (11%) IBLI patients without re-resection, within a median of 
12.4 months (IQR 6.8–13.3). Intestinal re-resection was performed in 5 out of 43 (16%) IBLI patients within a median of 3.7 
months (IQR 3.5–10.8).
Conclusion IBLI is associated with symptoms and an unfavorable outcome, with a high risk of endoscopic recurrence in the 
neoterminal ileum and intestinal re-resection during short-term follow-up. Therefore, the blind ileal loop needs to be assessed 
during endoscopy in postoperative CD patients. Eur J Gastroenterol Hepatol 31: 1370–1375
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6 months and subsequent step-up drug therapy for endo-
scopic recurrence, as endoscopic recurrence rates after 
18 months were significantly lower compared to patients 
with conventional drug therapy without colonoscopy [8].
Although the Rutgeerts score is a convenient tool 
during postoperative endoscopy and widely used to 
estimate the risk of recurrence, it has some limitations. 
Currently, a side-to-side ileocolonic anastomosis is most 
often used during CD surgery. As end-to-end anastomo-
sis was common at the time of publication of the orig-
inal Rutgeerts score, assessment of the Rutgeerts score 
is limited to the anastomosis and neoterminal ileum, 
while the blind ileal loop is not taken into account. The 
prevalence and outcome of isolated inflammation of the 
ileal blind loop are unknown. In this study, we aimed to 
assess the occurrence of isolated ileal blind loop inflam-
mation, associated risk factors and outcomes in postop-
erative CD patients.
Materials and methods
Study population
This multicenter, retrospective study was performed in 
the Erasmus MC, Rotterdam (academic center) and in the 
Amphia hospital, Breda (large teaching hospital). All adult 
CD patients (aged ≥18 years) who underwent an intestinal 
resection with ileocolonic anastomosis between January 
1997 and June 2017 were included. The study population 
was identified using Endobase (Olympus corp. Tokyo, 
Japan), a hospital endoscopy registry system in which 
the type of endoscopy, the indication and the endoscopy 
report are stored [11]. In this endoscopy registry, a search 
was performed using the terms (‘Crohn’ and ‘resection’) 
or ‘anastomosis’ or ‘Rutgeerts’ or ‘ileocecal’. Subsequently, 
all hospital records of the obtained patient population 
were hand searched for the date of surgery.
Data collection
Endoscopy reports of the selected patients were reviewed 
and endoscopic findings at the ileocolonic anastomosis 
were registered. Ileal blind loop inflammation (IBLI) was 
defined as isolated inflammation (erosions and/or ulcera-
tions) of the ileal blind loop with or without aphtous ulcers 
confined to the anastomosis. CD patients after ileoco-
lonic resection without IBLI were selected as background 
population. Patient and disease characteristics including 
demographics, disease phenotype and duration, smoking 
status and surgical history were collected from hospital 
records. Clinical charts were reviewed for the indication 
of colonoscopy and the presence of symptoms (increased 
stool frequency and/or abdominal pain) at the time of IBLI 
diagnosis. The start or step-up of CD medication within 3 
months after IBLI diagnosis was recorded. Follow-up data 
including performed endoscopies and subsequent surger-
ies were collected up to June 2017.
Outcome measures
Endoscopic recurrence was defined as extension of IBLI 
to the neoterminal ileum with Rutgeerts score i3 or i4, 
and surgical recurrence was defined as an intestinal 
re-resection.
Data analysis
IBM SPS Statistics version 24.0 (IBM Corp. Released 
2013, IBM Corp, Armon, New York) was used for sta-
tistical analysis. Continuous variables were described 
as medians and compared using Mann–Whitney U test. 
Categorical variables were described using proportions 
and percentages and compared using χ2 test. Survival sta-
tistics using Kaplan–Meier analysis was used to describe 
occurrence and time to IBLI diagnosis. The index date for 
survival analysis for the IBLI population was the date of 
the last surgery after which IBLI was observed. For the 
background population, the most recent surgery was 
selected as index date. Associated factors for IBLI were 
identified using Cox proportional hazard analysis. A 
P-value of <0.05 was accepted as statistically significant.
This study was conducted in accordance with the pro-
tocol and the principles of the Declaration of Helsinki. 
The study protocol was approved by the Medical Ethical 
Review Committee of the Erasmus University Medical 
Center on the 16th of August 2017.
Results
In total, 341 [132 male (39%)] postoperative CD patients 
were included. The ileal blind loop was described in the 
endoscopy report in 125 (37%) patients. IBLI was reported 
in 43 of 341 (13%) patients, of whom 19 (6%) patients 
had ulcerations limited to the blind loop, and 24 (7%) 
patients had IBLI combined with aphthous ulcers confined 
to the anastomosis (Fig. 1). The main indication for the 
endoscopy revealing IBLI was symptoms in 26 (60%) IBLI 
patients, followed by standard work-up after intestinal 
resection in 9 (21%) IBLI patients and effect monitoring 
of medical therapy in eight (19%) IBLI patients.
The baseline characteristics in the IBLI population 
(n = 43) showed no significant differences to the back-
ground population (n = 298), with regard to sex, Montreal 
Fig. 1. Flow chart of IBLI occurrence. IBLI, ileal blind loop inflammation.
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classification and smoking status. Family history of IBD 
was positive in 15 out of 43 (35%) IBLI patients, which 
was significantly more frequent compared to 57 of 298 
(19%) patients in the background cohort (P = 0.002). 
Furthermore, a significantly higher proportion of IBLI 
patients, 16/43 (37%) vs. 67/298 (23%) in the background 
population, had undergone multiple previous ileocolonic 
resections, P = 0.035 (Table 1).
Risk of ileal blind loop inflammation
The median time between the last resection and descrip-
tion of IBLI in the endoscopy report was 2.9 years [inter-
quartile range (IQR) 0.7–5.9] and the majority of IBLI 
cases (69.8%) occurred in the first 5 years after resection. 
Kaplan–Meier survival analysis showed that 5 years after 
the most recent intestinal resection, IBLI was described in 
the endoscopy report of 5.8% of the population. After 10 
years, IBLI was described in 14.2% of the patients at risk. 
IBLI without anastomotic ulcers was described in 4.5% and 
6.7% of patients, after 5 and 10 years, respectively (Fig. 2).
Consistent with the observed baseline characteristics, in 
univariable analysis, a positive family history of IBD [HR 
3.7, 95% confidence interval (CI) 1.8–7.8] and multiple 
previous ileocolonic resections (HR 2.3, 95% CI 1.2–4.3) 
were identified as factors associated with the occurrence 
of IBLI. In multivariable analysis, a positive family history 
of IBD remained a significant risk factor, HR 3.5, 95% CI 
1.5–7.4 (P < 0.001) (Table 2).
Clinical manifestation
A total of 32 out of 43 (74%) IBLI patients [14/19 (74%) 
IBLI without anastomotic ulcers and 18/24 (75%) IBLI 
with anastomotic ulcers] complained of abdominal pain 
and/or increased bowel movements at the time of endos-
copy revealing IBLI. Subsequent start or step-up drug 
therapy was initiated in 10 out of 32 (31%) symptomatic 
patients [5/14 (36%) true IBLI and 5/18 (27%) IBLI 
with anastomotic ulcers], within a median of 0.9 months 
(IQR 0.7–1.4) after colonoscopy. The following thera-
pies were initiated: mesalazine (one patient), budesonide 
(five patients), azathioprine (one patient) and anti-TNFα 
therapy (three patients). In one patient who underwent 
standard colonoscopy for recurrent inflammation, with-
out clinical symptoms, budesonide was initiated after the 
diagnosis of IBLI.
Outcome
Extension of inflammation to the neoterminal ileum 
(Rutgeerts score i3 or i4) occurred in 4 out of 38 (11%) 
patients without a subsequent resection during follow-up, 
within a median of 12.4 months (IQR 6.8–13.3) after IBLI 
diagnosis. Endoscopic recurrence in the background pop-
ulation was comparable, 45 out of 298 (15%) (P = 0.452), 
although the time to recurrence, within a median of 42.8 
months (IQR 16.7–90.2), was significantly longer com-
pared to IBLI patients (P = 0.013). Median total follow-up 
time was also significantly shorter in the IBLI cohort, 
Table 1. Baseline characteristics
IBLI (n = 43) Background (n = 298) P value
Male sex, n (%) 19 (44) 113 (38) 0.430
Family history of IBD, n (%) 15 (35) 57 (19) 0.002
Montreal A, 
n (%)
<17 year 4 (10) 43 (14) 0.618
17-40 year 32 (74) 203 (68)
>40 year 7 (16) 52 (18)  
Montreal L, 
n (%)
Ileum 20 (47) 131 (44) 0.889
Colon 0 (0) 11 (4)
Ileocolonic 23 (53) 156 (52)
Montreal B, 
n (%)
Luminal 15 (35) 135 (45) 0.294
Stricturing 23 (53) 122 (41)
Penetrating 5 (12) 41 (14)
Perianal disease, n (%) 6 (14) 67 (22.5) 0.196
Smoking, n (%) 23 (54) 138 (46) 0.270
Ileocolonic resections, n (%) 1 27 (63) 231 (77) 0.035
>1 16 (37) 67 (23)  
Time from resection to endoscopic evaluation in years, median (IQR) 2.9 (0.7–5.9) 1.5 (0.6–4.8) 0.092
IBD, inflammatory bowel disease; IBLI, ileal blind loop inflammation; IQR, interquartile range.
Fig. 2. Kaplan–Meier survival curve representing the percentage of IBLI occurrence during follow-up time after the most recent intestinal resection. IBLI, 
ileal blind loop inflammation; FU-time, follow-up time.
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median 1.9 years (IQR 0.9–4.4), compared to 7.0 years 
(IQR 3.9–12.1) in the background cohort (P < 0.001).
In five patients (16%), clinical symptoms led to a sub-
sequent resection during follow-up after IBLI diagnosis, 
within a median of 3.7 months (IQR 3.5–10.8). Three of 
these re-resections were revisions of the ileocolonic anas-
tomosis, after which all three patients experienced an 
immediate relieve of symptoms.
Discussion
The blind ileal loop at the ileocolonic anastomosis after 
intestinal resection in CD is erroneously disregarded. In 
this study, we have shown that a description of the ileal 
blind loop is lacking in nearly two-thirds of endoscopy 
reports in postoperative CD patients with a side-to-side 
ileocolonic anastomosis. This finding is in sharp contrast 
to our results that demonstrate an unfavorable disease 
course after IBLI diagnosis, with regard to a considerable 
risk of endoscopic recurrence and surgical re-resection, 
both at short-term follow-up. Furthermore, despite its 
association with symptoms, drug therapy is infrequently 
initiated or changed after IBLI diagnosis.
To the best of our knowledge, this study is the first 
to assess the occurrence rate and prognosis of IBLI. The 
side-to-side anastomosis is the preferred technique in ile-
ocolonic CD surgery after evidence of an advantage for 
the wider side-to-side when compared to end-to-end or 
end-to-side anastomosis in terms of anastomotic leakage, 
CD recurrence and re-resection risk [12–15]. Therefore, 
endoscopists are familiar with the anatomy of the side-to-
side ileocolonic anastomosis. Nevertheless, we observed 
that a description of the ileal blind loop is missing in the 
majority of endoscopy reports. As a consequence, this 
retrospective cohort provides insufficient data to give an 
accurate estimation of IBLI prevalence. Considering that a 
description of the blind loop is often lacking in endoscopy 
reports, IBLI occurrence might yet be underestimated. 
Hence, the detection rate of IBLI needs to be confirmed in 
a larger prospective study.
The etiology of IBLI is unknown, and may be different 
from the etiology of recurrent CD lesions in the neoter-
minal (afferent) ileum. Hypotheses that warrant consid-
eration include ischemia, disturbance of the microbiome 
by fecal stasis and diversion ileitis. The first potential 
mechanism underlying IBLI might be ischemia in the top 
of the blind loop, similar to the suggested pathophysiology 
of recurring ulcers confined to the anastomosis (Rutgeerts 
score i2a) [16]. Second, stasis of bowel content may cause 
bacterial overgrowth, similar to diarrhea caused by blind 
loop syndrome after bariatric surgery [17,18]. Although 
small intestinal bacterial overgrowth has previously been 
observed in CD patients [19], it has never been linked to 
the development of endoscopic ulcers. Third, diversion ile-
itis may be the most plausible etiology of IBLI. Diversion 
of the fecal stream could induce inflammation, similar to 
diversion colitis. The pathophysiology of diversion coli-
tis is not fully elucidated, and may be a combination of 
ischemia caused by a shortage of short chain fatty acids 
causing increased arteriolar resistance and dysbiosis [20]. 
Current insights in the pathogenesis of CD advocate an 
important role for the decreased diversity of the gut flora 
in the perpetuating activation of inflammation [21]. Also 
in the setting of postoperative CD, early studies have sug-
gested an important influence of the microbiota by demon-
strating a benefit of metronidazole in the prevention of 
postoperative CD recurrence [22]. More recent studies 
showed microbiome diversity was decreased after CD sur-
gery [23], and alterations in gut microbiota distribution 
around the anastomosis were associated with postoper-
ative endoscopic recurrence [24]. The microbiome in the 
blind ileal loop needs to be further studied. In this respect, 
the length of the created ileal blind loop could be of inter-
est, as a long segment may be associated with dysbiosis. 
Unfortunately, details on the length of the ileal blind loop 
in our series are lacking. Our results showed that three 
patients became asymptomatic after surgical revision of 
the side-to-side anastomosis, which supports that the ana-
tomical composition of the side-to-side anastomosis could 
be relevant in the development of IBLI.
Known risk factors associated with postoperative 
endoscopic recurrence in the neoterminal ileum, for 
example, smoking and penetrating disease [9,25] were not 
associated with IBLI in our study. Significantly more IBLI 
patients had undergone multiple resections before base-
line. Although this factor was not significantly associated 
with IBLI in multivariable analysis, it might suggest a more 
aggressive disease course and could have contributed to 
a higher postoperative recurrence rate in IBLI patients. 
Further assessment in a larger cohort is necessary to 
Table 2. Hazard ratios of factors possibly associated with ileal blind loop inflammation in univariable and multivariable regression analysis
Univariable analysis Multivariable analysis
HR 95% CI P value HR 95% CI P value
Male sex 1.2 0.7–2.4 0.408    
Montreal A <17 year 1 Ref Ref    
17–40 year 1.9 0.7–5.3 0.232    
>40 year 1.6 0.5–5.4 0.463    
Montreal L Ileum 1 Ref Ref   
Ileocolonic 0.8 0.5–1.6 0.666   
Montreal B Luminal 1 Ref Ref    
Stricturing 1.6 0.8–3.0 0.168    
Penetrating 1.2 0.4–3.3 0.741    
Perianal disease 0.5 0.2–1.3 0.164    
Active or previous smoking 1.4 0.7–2.8 0.312    
IBD family history 3.7 1.8–7.8 <0.001 3.5 1.6–7.4 <0.001
Time from diagnosis to first resection 1.0 0.9–1.1 0.256    
Age at first resection 1.0 0.9–1.0 0.676    
Multiple ileocolonic resections 2.3 1.2–4.3 0.009 1.4 0.6–3.2 0.376
CI, confidence interval; HR, hazard ratio; IBD, inflammatory bowel disease; IBLI, ileal blind loop inflammation.
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provide a balanced analysis of this potential confounding 
factor. In our study, a positive family history for IBD was 
the only factor significantly associated with IBLI in multi-
variable analysis. Hypothetically, the association between 
a positive IBD family history and IBLI in postoperative 
CD patients might be explained by gene variations that 
play a role in microbiome dysbiosis. For instance, NOD2 
gene mutations are common in CD familial heredity and 
are associated with a deficient antimicrobial response and 
immune regulatory dysfunction [26–28].
IBLI patients seem to have an unfavorable prognosis 
considering high re-resection rates within a short time 
period after IBLI diagnosis. Endoscopic progression of 
the inflammation to the neoterminal ileum (i.e. Rutgeerts 
score i3/i4) was observed in 11% within 5 years. In the 
background population, we observed progression to 
Rutgeerts score i3/i4 within 5 years in 5% for Rutgeerts 
score i2a at first postoperative endoscopy, and 60% for 
Rutgeerts score i2b. It could be speculated that IBLI should 
be placed between i2a and i2b in a revised Rutgeerts score. 
However, the timing of the endoscopies in both groups in 
this study differs considerably and a firm conclusion can-
not be drawn. Future prospective research with standard-
ized timing of colonoscopies is needed before adding IBLI 
to a revised Rutgeerts score.
This retrospective study, assessing detailed information 
collected from endoscopy reports and hospital charts of 
an academic center and a large teaching hospital, serves 
as a plea for further prospective evaluation of IBLI, with 
regard to pathophysiology, prevalence and prognosis. 
Evidently, a few limitations of this study, inherent to its 
retrospective design, need to be considered. First, patients 
were not followed or treated according to a standardized 
follow-up protocol. This might have led to an underestima-
tion of IBLI occurrence, since the majority of endoscopies 
were performed on indication of symptoms. Furthermore, 
the index date differed between both cohorts. For IBLI 
patients, the index date was the last surgery before the 
endoscopy revealing IBLI, while in the background pop-
ulation the last surgery overall was chosen. Although 
the index dates were deliberately determined to allow 
for the most reliable and accurate comparison between 
both cohorts, follow-up and outcome results need to be 
interpreted with care. Nonetheless, our retrospective data 
enable interpretation of the results in a real-world set-
ting, which provides insight in the occurrence and con-
sequences of IBLI in everyday clinical practice. Second, 
endoscopy reports were not uniform and endoscopists 
might have assessed the ileal blind loop during postoper-
ative endoscopy, but might not have included a descrip-
tion in the endoscopy report. Especially during earlier 
follow-up years, when endoscopy reports were less stand-
ardized and guidelines on postoperative endoscopies were 
not yet published, blind loop assessments might have been 
underreported in our study. A sensitivity analysis regard-
ing the outcome endoscopic recurrence was performed 
in a selection of patients with a description of the blind 
loop in the endoscopy report (n = 125), which showed an 
overall increase from 15 to 19% endoscopic recurrence 
in the background population compared to 11% in IBLI 
patients, P = 0.181. Third, because IBLI was described 
more often in endoscopy reports from more recent cal-
endar years, total follow-up time was shorter in the IBLI 
cohort as compared to the background cohort, hampering 
interpretation of the comparison of endoscopic recurrence 
between both cohorts. Shorter follow-up might have led to 
lower endoscopic recurrence rates. Finally, the study pop-
ulation was too small to allow for in-depth analysis of risk 
factors for IBLI.
In conclusion, the blind ileal loop is often disregarded 
during postoperative ileocolonoscopy. Nevertheless, it 
is associated with symptoms and this study suggests an 
unfavorable prognosis of IBLI, as a high risk of surgical 
recurrence during follow-up was observed. Therefore, the 
blind ileal loop needs to be assessed during endoscopy in 
postoperative CD patients with ileocolonic anastomosis, 
both in clinical practice and in prospective research.
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